1[1]Hudson MP, Granger CB, Topol E J, et al. Early reinfarction after fibrinolysis:experience from the global utilization of streptokinase and tissue plasminogen activator(alteplase)for occluded coronary arteries (GUSTO - Ⅰ )and global use of sStrategies to open occluded coronary arteries ( GUSTO - Ⅲ ) trials [ J ]. Circulation, 2001,104:1 229.
2[2]ISIS - 2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase,oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2 [J]. Lancet, 1988, 2(8 607) :349.
3[3]Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - Ⅰ: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [ J ] . BMJ, 1994,308(6 921 ) :81.
4[4]The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14[J] . Eur Heart J,2000,21(23) :1 944.
5[5]The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ⅱ b/Ⅲ a inhibition: The GUSTO Ⅴ randomized trial[J]. Lancet, 2001,357:1 905.
6[6]Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of aboiximab with and without low- dose reteplase for acute myocardial infarction[J]. Circulation, 2000,101(24) :2 788.
7[7]Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin repeffusion therapy (HART Ⅱ )[J]. Circulation, 2001,104:648.
8[8]Baird SH, Menown IB, Mcbride SJ, et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction[J]. Eur Heart J, 2002,23(8) :627.
9[9]The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT) -3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction[J]. Lancet, 2001,358(9 282) :605.
10[10]Antman EM, Louwerenburg HW, Baars HF, et al. For the ENTIRE-TIMI 23 Investigators. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trail[J]. Circulation, 2002,105:1 642.
